Oppenheimer Starts ArriVent BioPharma at Outperform
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint
Oral Weight Loss Drugs Vs. Injections - Pills Are Promising Yet Challenging Frontier
The race to develop oral weight loss medications is intensifying as companies like Roche Holdings AG (OTC:RHHBY), Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE)
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
Gilead Sciences (NASDAQ:GILD) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.The table below offers a condensed view of their
Alvotech Launches First Biosimilar of J&J's Stelara in Europe
Gilead Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 -3.49% Cantor Fitzgerald $75 → $70 Maintains Neutral 07/08/2024 28.22% Raymond James → $93
muhamad Hazairudin s : Muhammad Hazairudin Shadan